Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Board Changes

20 Oct 2021 07:00

RNS Number : 5782P
Roquefort Investments PLC
20 October 2021
 

20 October 2021

 

 

Roquefort Investments plc

("Roquefort Investments" or the "Company")

 

Board Changes

 

Roquefort Investments (LSE:ROQ), the investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, announces the appointment of Mr Mark Freeman as a non-executive director and the resignation of Mr Glenn Whiddon as non-executive director with effect from today.

 

Mr Freeman (aged 46) is a Chartered Accountant and has more than 25 years' experience in corporate finance and the public markets, with a focus on project development. Mr Freeman is a graduate of the University of Western Australia with a Bachelor of Commerce with a double major in Banking & Finance and Accounting as well as holding a Graduate Diploma in Applied Finance with a major in Investment Analysis from the Securities Institute of Australia. He has experience in strategic planning, business development, acquisitions and mergers, project commercialisation, project development and general management. Mr Freeman is currently a director of Pursuit Minerals Ltd (ASX:PUR), Calima Energy Ltd (ASX:CE1) and Grand Gulf Energy Ltd (ASX:GGE).

 

In addition, Mr Freeman is currently a director of Lyramid Limited ("Lyramid"). It is intended that Mr Freeman will retain his position as one of the two Australian resident directors required to be appointed to the Board of Lyramid after the proposed acquisition of Lyramid has completed.

 

Stephen West, Executive Chairman, commented:

"As we work towards completion of the Lyramid transaction, it is important to have a financially oritentated Australian resident director with public markets experience to assist the Company going forward. We are therefore delighted that Mark Freeman has agreed to join the Company as a non-executive director given his proven track record and experience in this regard. I would like to thank Glenn Whiddon for working with us from the formation of Roquefort Investments up to this transformational stage for the Company.

 

The Board is focused on completing the Lyramid transaction and the RTO process and we look forward to providing a further update on this shortly."

 

Enquiries:

 

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Joint Broker)

 

Christian Dennis

+44 (0) 20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFFEFIUEFSEIS
Date   Source Headline
6th Feb 20247:00 amRNSOperations Update
24th Nov 20237:00 amRNSChange of Auditor
6th Nov 20237:00 amRNSSignificant Mesodermal Killer Cell Milestone
27th Sep 20237:00 amRNSInterim Results to 30 June 2023
22nd Sep 202311:42 amRNSInvestor Presentation via Investor Meet Company
14th Aug 20237:00 amRNSExpansion of Patent Portfolio
7th Aug 20237:00 amRNSDevelopment of New Novel siRNA Therapeutics
2nd Aug 20237:00 amRNSDirector/PDMR Shareholding
12th Jul 202310:27 amRNSDirector/PDMR Shareholding
29th Jun 202310:05 amRNSResults of AGM
29th Jun 20237:00 amRNSAGM Statement
27th Jun 20237:00 amRNSInvestor Presentation via Investor Meet Company
26th Jun 20232:41 pmRNSDirector/PDMR Shareholding
26th Jun 202310:36 amRNSDirector/PDMR Shareholding
26th Jun 202310:00 amRNSDirector/PDMR Shareholding
22nd Jun 20237:00 amRNSRNA Medicine Shows In Vitro Anti-Cancer Efficacy
19th Jun 20237:00 amRNSAntibody Program Results & Orphan Drug Indication
13th Jun 20237:00 amRNSAnti-Cancer MDK mRNA - Positive in vitro Results
7th Jun 202310:11 amRNSRestoration of Trading
6th Jun 20237:00 amRNSNotice of Annual General Meeting
5th Jun 20237:00 amRNSAnnual Report & Financial Statements - 31 Dec 2022
2nd May 20237:56 amRNSSuspension of Trading Pending 2022 Annual Report
2nd May 20237:30 amRNSSuspension - Roquefort Therapeutics plc
13th Mar 20237:30 amRNSConfirmation of No Exposure to Silicon Valley Bank
8th Mar 20237:00 amRNSCreation of New Novel Family of mRNA Therapeutics
6th Mar 20237:00 amRNSFormation of Scientific Advisory Board
1st Mar 20237:00 amRNSCompany Presentation
21st Feb 20237:00 amRNSInvestor Presentation
20th Feb 20237:00 amRNSRandox Licence and Royalty Agreement
24th Jan 20237:00 amRNSMDK Oncology Antibodies Demonstrate In-Vivo Safety
18th Jan 20238:36 amRNSHolding(s) in Company
16th Jan 20237:00 amRNSAppointment of Auditor
9th Jan 20237:00 amRNSOperations Update
5th Dec 20228:07 amRNSPresentation of Midkine Oligonucleotide Program
1st Dec 20222:00 pmRNSResignation of Auditor
25th Oct 20227:00 amRNSMidkine Antibody Program - Festival of Biologics
11th Oct 20227:00 amRNSROQ Presents Study Results at the ESGCT Conference
28th Sep 20227:00 amRNSDirector/PDMR Shareholding
26th Sep 20222:30 pmRNSDirector/PDMR Shareholding
23rd Sep 20227:00 amRNSInterim Results to 30 June 2022
23rd Sep 20227:00 amRNSInterim Results to 30 June 2022
16th Sep 20228:00 amRNSInvestor Presentation
16th Sep 20227:01 amRNSBoard and Management Appointments
16th Sep 20227:00 amRNSAcquisition Completion, Admission & Voting Rights
15th Sep 202212:26 pmRNSNotice of Admission
13th Sep 202211:08 amRNSPublication of Prospectus
11th Aug 20227:00 amRNSPre-clinical Program & Transaction Update
20th Jul 20227:00 amRNSAppointment of Joint Broker
15th Jul 20227:00 amRNSCommencement of Trading on US OTCQB Venture Market
4th Jul 20224:57 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.